Search
lomitapide (Juxtapid)
Indications:
- FDA-approved as an orphan drug (Dec 2012) to treat homozygous familial hypercholesterolemia
Mechanism of action:
- inhibits the microsomal triglyceride transfer protein MTTP necessary for VLDL assembly & secretion in the liver
- reduces LDL cholesterol, total cholesterol, apolipoprotein B, & non-HDL cholesterol
Interactions
drug adverse effects of anti-hyperlipidemic agents
General
anti-hyperlipidemic agent
Database Correlations
PUBCHEM correlations
References
- Wikipedia: Lomitapide
http://en.wikipedia.org/wiki/Lomitapide
- Raal FJ
Lomitapide for homozygous familial hypercholesterolaemia.
The Lancet, Volume 381, Issue 9860, Pages 7 - 8, 5 January 2013
PMID: 23122767
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)61845-5/fulltext
- FDA Approves Aegerion Pharmaceuticals' JUXTAPID(TM) (lomitapide)
Capsules for Homozygous Familial Hypercholesterolemia (HoFH)
http://ir.aegerion.com/releasedetail.cfm?ReleaseID=728650